At a glance
ClinicalIndex Comparison RecordN/ACompleted· 29 enrolled
Drug / intervention
Myforticdrug
Likely dose
Myfortic 360mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Conversion of CellCept to Myfortic: A Prospective Study on the Tolerability and Safety of Myfortic in Liver Transplant Recipients
In Brief
A clinical study evaluating Myfortic for Immunosuppression. Completed, enrolled 29 participants across 1 site.
Detailed Summary
The objective of this study is to determine the tolerability and safety of Myfortic in liver transplant patients. Patients receiving CellCept who have GI side effects will have CellCept discontinued and changed to Myfortic (Myfortic is a new drug similar to CellCept, except it is enteric-coated). Our hypothesis is that Myfortic has less GI side effects and will, therefore, be tolerated better than CellCept and also that Myfortic will have a comparable effectiveness to CellCept.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunosuppression
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2006
Enrollment StartNov 2006
Primary CompletionNov 2008
TodayJul 2026
First PostedJun 14, 2006
Enrollment StartNov 1, 2006
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 20.1 years ago
Interventions
Myforticdrug
Myfortic 360mg or 720 mg BID for 90 days.